Literature DB >> 21417919

Both exogenous subclinical hyperthyroidism and short-term overt hypothyroidism affect myocardial strain in patients with differentiated thyroid carcinoma.

Randa M Abdulrahman1, Victoria Delgado, Hendrieke C Hoftijzer, Arnold C T Ng, See Hooi Ewe, Nina Ajmone Marsan, Eduard R Holman, Guido C Hovens, Eleonora P Corssmit, Johannes A Romijn, Jeroen J Bax, Johannes W A Smit.   

Abstract

BACKGROUND: The cardiovascular effects of transitions from exogenous subclinical hyperthyroidism to short-term overt hypothyroidism in patients treated for differentiated thyroid carcinoma remain unclear. The present study aims at evaluating the changes in multidirectional myocardial strain using two-dimensional (2D) speckle tracking during this controlled transition from exogenous subclinical hyperthyroidism to overt hypothyroidism.
METHODS: The study included 14 patients with differentiated thyroid carcinoma on thyrotropin suppressive thyroxine substitution who were subsequently withdrawn from thyroxine for 4 weeks. Cardiac function was assessed by 2D speckle tracking echocardiography before and 1 and 4 weeks after withdrawal and compared with values obtained in a control group of 24 individuals.
RESULTS: At baseline, the left ventricular dimensions were significantly higher in patients as compared with controls. Using 2D speckle tracking imaging, the patients had significantly impaired baseline myocardial systolic function in the circumferential (-16.0% ± 2.1% vs. -19.2% ± 3.0%, p = 0.001) and longitudinal (-17.1% ± 2.5% vs. -19.7% ± 3.0%, p = 0.001) directions as compared with controls. Withdrawal of thyroid hormone did not induce significant changes in left ventricular dimensions or systolic function. During the transition from exogenous subclinical hyperthyroidism to overt hypothyroidism, a significant improvement in circumferential and longitudinal systolic shortening was observed and returned to abnormal values when the patients were overt hypothyroid (circumferential strain: from -16.0% ± 2.1% to -18.6% ± 1.9% and -14.7% ± 2.8%, p < 0.005; longitudinal strain: from -17.1% ± 2.5% to -18.8% ± 1.4% and -16.3% ± 1.3%, p < 0.005).
CONCLUSIONS: A U-shaped relationship between a range of thyroid hormone levels (from hyper- to hypothyroid concentrations) and myocardial strains was observed. The clinical consequences of these findings remain to be determined but may point out an increased myocardial vulnerability even in states of moderate subclinical hyperthyroidism and short-term hypothyroidism.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21417919     DOI: 10.1089/thy.2010.0319

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  13 in total

Review 1.  Radioiodine Treatment and Thyroid Hormone Suppression Therapy for Differentiated Thyroid Carcinoma: Adverse Effects Support the Trend toward Less Aggressive Treatment for Low-Risk Patients.

Authors:  E N Klein Hesselink; T P Links
Journal:  Eur Thyroid J       Date:  2015-06-11

2.  Risk Factors for Cardiovascular Disease Among Thyroid Cancer Survivors: Findings From the Utah Cancer Survivors Study.

Authors:  Jihye Park; Brenna E Blackburn; Patricia A Ganz; Kerry Rowe; John Snyder; Yuan Wan; Vikrant Deshmukh; Michael Newman; Alison Fraser; Ken Smith; Kim Herget; Anne C Kirchhoff; Dev Abraham; Jaewhan Kim; Marcus Monroe; Mia Hashibe
Journal:  J Clin Endocrinol Metab       Date:  2018-07-01       Impact factor: 5.958

3.  Thyroid cancer: Balancing benefit and risk in TSH management of DTC.

Authors:  Frederik A Verburg; Markus Luster
Journal:  Nat Rev Endocrinol       Date:  2018-01-19       Impact factor: 43.330

4.  Serum TSH levels are associated with postoperative recurrence and lymph node metastasis of papillary thyroid carcinoma.

Authors:  Yingying Xiang; Yiying Xu; Adheesh Bhandari; Namita Sindan; Suzita Hirachan; Qing Yang; Guilong Guo; Yanyan Shen
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

5.  Changes in cardiac function and structure in newly diagnosed Graves' disease. A conventional and 2D-speckle tracking echocardiography study.

Authors:  K Aroditis; M Pikilidou; E Vourvouri; L Hadjistavri; P Zebekakis; J Yovos; G Efthimiadis; H Karvounis
Journal:  Int J Cardiovasc Imaging       Date:  2016-09-28       Impact factor: 2.357

6.  Cardiovascular Incidence in 6900 Patients with Differentiated Thyroid Cancer: a Swedish Nationwide Study.

Authors:  Maximilian Zoltek; Therese M-L Andersson; Christel Hedman; Catharina Ihre-Lundgren; Caroline Nordenvall
Journal:  World J Surg       Date:  2020-02       Impact factor: 3.352

7.  Incident atrial fibrillation in patients with differentiated thyroid cancer: a meta-analysis.

Authors:  Georgios Kostopoulos; Ioannis Doundoulakis; Christina Antza; Emmanouil Bouras; Krishnarajah Nirantharakumar; Dimitrios Tsiachris; G Neil Thomas; Gregory Y H Lip; Konstantinos A Toulis
Journal:  Endocr Relat Cancer       Date:  2021-04-29       Impact factor: 5.678

Review 8.  Long-term treatment-related morbidity in differentiated thyroid cancer: a systematic review of the literature.

Authors:  William Ae Parker; Ovie Edafe; Sabapathy P Balasubramanian
Journal:  Pragmat Obs Res       Date:  2017-05-16

9.  External Cardioversion of Atrial Fibrillation Causes an Early Improvement of Cardiac Performance: A Longitudinal Strain Analysis Study.

Authors:  Stefano Fumagalli; Debbie Gabbai; Sara Francini; Marta Casalone Rinaldi; Stefano Pedri; Samuele Baldasseroni; Francesca Tarantini; Claudia Di Serio; Giuseppe Lonetto; Mauro Di Bari; Luigi Padeletti; Harry J Crijns; Niccolò Marchionni
Journal:  J Cardiovasc Echogr       Date:  2014 Jan-Mar

Review 10.  Pro-Arrhythmic Signaling of Thyroid Hormones and Its Relevance in Subclinical Hyperthyroidism.

Authors:  Narcis Tribulova; Lin Hai Kurahara; Peter Hlivak; Katsuya Hirano; Barbara Szeiffova Bacova
Journal:  Int J Mol Sci       Date:  2020-04-19       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.